MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2024.1344184

Медицинская библиотека · Frontiers in immunology · 2024

Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study.

Vogrig Alberto, Tartaglia Sara, Dentoni Marta, Fabris Martina, Bax Francesco, Belluzzo Marco, Verriello Lorenzo, Bagatto Daniele, Gastaldi Matteo, Tocco Pierluigi, Zoccarato Marco, Zuliani Luigi, Pilotto Andrea, Padovani Alessandro, Villagrán-García Macarena, Davy Vincent, Gigli Gian Luigi, Honnorat Jérôme, Valente Mariarosaria

Многоцентровое исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

COVID-19 vaccines have been approved due to their excellent safety and efficacy data and their use has also permitted to reduce neurological complications of SARS-CoV-2. However, clinical trials were underpowered to detect rare adverse events. Herein, the aim was to characterize the clinical spectrum and immunological features of central nervous system (CNS) immune-related events following SARS-CoV-2 vaccination.

METHODS

Multicenter, retrospective, cohort study (December 1, 2020-April 30, 2022). Inclusion criteria were (1) de novo CNS disorders developing after SARS-CoV-2 vaccination (probable causal relationship as per 2021 Butler criteria) (2); evidence for an immune-mediated etiology, as per (i) 2016 Graus criteria for autoimmune encephalitis (AE); (ii) 2015 Wingerchuk criteria for neuromyelitis optica spectrum disorders; (iii) criteria for myelitis.

RESULTS

Nineteen patients were included from 7 tertiary referral hospitals across Italy and France (one of them being a national referral center for AE), over almost 1 year and half of vaccination campaign. Vaccines administered were mRNA-based (63%) and adenovirus-vectored (37%). The median time between vaccination and symptoms onset was 14 days (range: 2-41 days). CSF was inflammatory in 74%; autoantibodies were detected in 5%. CSF cytokine analysis (n=3) revealed increased CXCL-10 (IP-10), suggesting robust T-cell activation. The patients had AE (58%), myelitis (21%), acute disseminated encephalomyelitis (ADEM) (16%), and brainstem encephalitis (5%). All patients but 2 received immunomodulatory treatment. At last follow-up (median 130 days; range: 32-540), only one patient (5%) had a mRS>2.

CONCLUSION

CNS adverse events of COVID-19 vaccination appear to be very rare even at reference centers and consist mostly of antibody-negative AE, myelitis, and ADEM developing approximately 2 weeks after vaccination. Most patients improve following immunomodulatory treatment.

Для цитирования: Vogrig Alberto, Tartaglia Sara, Dentoni Marta, Fabris Martina, Bax Francesco, Belluzzo Marco, Verriello Lorenzo, Bagatto Daniele, Gastaldi Matteo, Tocco Pierluigi, Zoccarato Marco, Zuliani Luigi, Pilotto Andrea, Padovani Alessandro, Villagrán-García Macarena, Davy Vincent, Gigli Gian Luigi, Honnorat Jérôme, Valente Mariarosaria. Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study.. Frontiers in immunology. 2024. DOI: 10.3389/fimmu.2024.1344184.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.